Axsome Therapeutics, Inc. (LON: 0HKF)
London
· Delayed Price · Currency is GBP · Price in USD
101.08
+6.85 (7.27%)
Jan 22, 2025, 7:15 PM BST
Axsome Therapeutics Employees
Axsome Therapeutics had 545 employees as of December 30, 2023. The number of employees increased by 162 or 42.30% compared to the previous year.
Employees
545
Change (1Y)
162
Growth (1Y)
42.30%
Revenue / Employee
416.02K GBP
Profits / Employee
-382.21K GBP
Market Cap
4.02B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
ConvaTec Group | 10,136 |
Hikma Pharmaceuticals | 9,100 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Axsome Therapeutics News
- 23 days ago - Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results - Seeking Alpha
- 23 days ago - Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results - Benzinga
- 23 days ago - Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation - Investor's Business Daily
- 24 days ago - Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 24 days ago - Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 24 days ago - Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study - Reuters
- 24 days ago - Axsome Therapeutics Inc (AXSM) Announces Positive Phase 3 Trial Results for AXS-05 in ... - GuruFocus
- 24 days ago - Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation - GlobeNewsWire